Immune checkpoint inhibitors (ICIs) targeting PD-(L)1 and CTLA-4 have revolutionized treatment of advanced NSCLC, both as monotherapies and in combination with chemotherapy (Reck et al., 2021). Here, CD274 is linked to non-small cell lung carcinoma.